Cisplatin, Gemcitabine, and Sodium Glycididazole Combination

The combination of cisplatin, gemcitabine, and sodium glycididazole is a therapeutic regimen used primarily in cancer treatment, particularly for non-small cell lung cancer (NSCLC). This combination leverages the synergistic effects of these agents to enhance treatment efficacy. ## Description This is a three-drug combination therapy consisting of: 1. **Cisplatin** - A platinum-based chemotherapy drug that works by damaging DNA and preventing cancer cells from dividing[1][3]. 2. **Gemcitabine** - A nucleoside analog that inhibits DNA synthesis and repair, showing activity against various cancers including NSCLC[1][2][3]. 3. **Sodium Glycididazole (CMNa)** - A radiosensitizer that enhances the efficacy of radiotherapy and chemotherapy, particularly in hypoxic tumor cells[4][6][8]. The combination works through multiple mechanisms: cisplatin causes DNA damage, gemcitabine inhibits DNA repair and synthesis, and sodium glycididazole enhances these effects, particularly in hypoxic tumor environments. Clinical studies have shown that adding sodium glycididazole to gemcitabine-cisplatin therapy significantly improves response rates in NSCLC patients (85.5% vs 63.4% in one study)[4].